Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA

References

• Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401:1039–1052. doi:10.1016/S0140-6736(22)01468-4
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508–513. doi:10.1016/j.jhep.2010.01.007
   PubMed Web of Science ®Google Scholar
• Locarnini S, Bowden S. Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology. 2012;56:411–414. doi:10.1002/hep.25732
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Iwasaki Y, Aimi M, et al. Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance. JGH Open. 2020;4:698–706. doi:10.1002/jgh3.12321
   PubMed Web of Science ®Google Scholar
• Martinez MG, Boyd A, Combe E, et al. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75:706–717. doi:10.1016/j.jhep.2021.05.013
   PubMed Web of Science ®Google Scholar
• Tantiwetrueangdet A, Panvichian R, Sornmayura P, et al. Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues. Med Oncol. 2018;35:127. doi:10.1007/s12032-018-1191-7
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Maekawa S, Komatsu N, et al. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol Res. 2019;49:51–63. doi:10.1111/hepr.13277
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141:517–525.e2. doi:10.1053/j.gastro.2011.04.046
   PubMed Web of Science ®Google Scholar
• Mak LY, Seto WK, Fung J, et al. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int. 2020;14:35–46. doi:10.1007/s12072-019-09998-5
   PubMed Web of Science ®Google Scholar
• Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–482. doi:10.1053/j.gastro.2010.04.048
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Yoon K, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–430. doi:10.1002/hep.23327
   PubMed Web of Science ®Google Scholar
• Liu J, Wang T, Zhang W, et al. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14:958–972. doi:10.1007/s12072-020-10099-x
   PubMed Web of Science ®Google Scholar
• Ghany MG, Buti M, Lampertico P, et al. 2022 AASLD-EASL HBV-HDV treatment endpoints conference faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference. J Hepatol. 2023;79:1254–1269.
   PubMedGoogle Scholar
• Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58:546–554. doi:10.1002/hep.26385
   PubMed Web of Science ®Google Scholar
• Liu J, Yang HI, Lee MH, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology. 2014;60:77–86. doi:10.1002/hep.27083
   PubMed Web of Science ®Google Scholar
• Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165:1025–1040. doi:10.1053/j.gastro.2023.05.053
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526. doi:10.1053/jhep.2003.50346
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Kao JH, Hu TH, Jia J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540–1550. doi:10.1111/apt.16097
   PubMed Web of Science ®Google Scholar
• Koffas A, Kumar M, Gill US, et al. Chronic hepatitis B: the demise of the ‘inactive carrier’ phase. Hepatol Int. 2021;15:290–300. doi:10.1007/s12072-021-10137-2
   PubMed Web of Science ®Google Scholar
• Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138:1747–1754. doi:10.1053/j.gastro.2010.01.042
   PubMed Web of Science ®Google Scholar
• Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2020;26:261–279. doi:10.3350/cmh.2020.0032
   PubMed Web of Science ®Google Scholar
• Lim TH, Gane E, Moyes C, et al. HBsag loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes. Hepatol Int. 2016;10:829–837. doi:10.1007/s12072-016-9709-6
   PubMed Web of Science ®Google Scholar
• Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58:853–860. doi:10.1016/j.jhep.2012.12.006
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Asselah T, Marcellin P. HBsag quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int. 2015;35(Suppl 1):82–90. doi:10.1111/liv.12735
   PubMedGoogle Scholar
• Han ZG, Qie ZH, Qiao WZ. HBsag spontaneous seroclearance in a cohort of HBeAg-seronegative patients with chronic hepatitis B virus infection. J Med Virol. 2016;88:79–85. doi:10.1002/jmv.24311
   PubMed Web of Science ®Google Scholar
• Seto WK, Wong DKH, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology. 2012;56:812–819. doi:10.1002/hep.25718
   PubMed Web of Science ®Google Scholar
• Kim JH, Ghosh A, Ayithan N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep. 2020;10:1835. doi:10.1038/s41598-020-58870-2
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514–522. doi:10.1016/j.jhep.2010.01.014
   PubMed Web of Science ®Google Scholar
• Kim YJ, Cho HC, Choi MS, et al. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int. 2011;31:817–823. doi:10.1111/j.1478-3231.2011.02516.x
   PubMed Web of Science ®Google Scholar
• Huang DQ, Li X, Le MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients With indeterminate phase. Clin Gastroenterol Hepatol. 2022;20:1803–1812.e5. doi:10.1016/j.cgh.2021.01.019
   PubMed Web of Science ®Google Scholar
• Choi GH, Kim GA, Choi J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther. 2019;50:215–226. doi:10.1111/apt.15311
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–1465. doi:10.1053/j.gastro.2007.08.039
   PubMed Web of Science ®Google Scholar
• Pearlman B. Hepatitis delta infection: a clinical review. Semin Liver Dis. 2023;43:293–304. doi:10.1055/a-2133-8614
   PubMed Web of Science ®Google Scholar
• Negro F, Lok AS. Hepatitis D: a review. JAMA. 2023;330:2376–2387. doi:10.1001/jama.2023.23242
   PubMed Web of Science ®Google Scholar
• Lai JC, Wong GL, Wong VW, et al. Unmet need in screening for hepatitis D virus: time to take action. J Hepatol. 2023; S0168-8278(23)05360-6.
   Google Scholar
• Shenoy A, Fontana RJ. HDV screening in chronic HBV: an unmet need of growing importance. Hepatology 2023.
   PubMed Web of Science ®Google Scholar